The Company was originally incorporated as a Private Limited Company on 10th June, 1985 in the state of Maharastra, Bombay and subsequently converted into a Public Limited Company on 4th January, 1994 and obtained certificate of change of name from the Registrar of Companies on 31 st January, 1994. The Company has been promoted by 'BHUTA' Family. The Bhuta family is having interest in various business activities such as manufacturing and marketing of pharmaceutical formulations, trading in Chemicals, Textiles etc. The group turnover in the year 1992-93 was Rs. 1616.85 lacs and over Rs. 2000 Lacs, (provisional) for the year 1993-94. Now the Company has taken over the existing business of a group partnership firm i.e. M/s Jenburkt Pharmaceuticals, a going concern which was engaged in the manufacturing and marketing of pharmaceuticals formulation on Loan Licence basis under various brand name registered with appropriate authorities in the name of firm. Brief history of the said partnership firm is as under: M/S Jenburkt Pharmaceuticals was established in the year 1984-85 by Mr. Harshad Bhuta along with his brothers. Initially the firm started, manufacturing and marketing of pharmaceuticals formulations under loan and licence basis. Mainly the products under different therapeutic group namely nutritional supplement, cough syrup-expectorant, Haematinic syrup. Initially the firm had launched their products only in Bombay and some parts of Maharashtra, Gujarat and Madhya Pradesh. Over last Ten years the firm had successfully launched more than 15 products and it has expanded its marketing 10 times to include areas like metropolitan Delhi, Key areas of Uttar Pradesh, Rajasthan, Haryana, Karnataka, Goa, Andhra Pradesh and Kerala. Its field force had consistently grown from 25 to 170 people. Jenburkt Products were made available through a wide spread network of stockists and super stockists through whom the products were distributed to thousands of retail chemist outlets. The firm had a consistent track record of growth and its turnover had increased to Rs. 484 Lacs during 1993-94 from Rs. 39.92 Lacs in the year 1985-86. MAIN OBJECTS OF THE COMPANY THE MAIN OBJECTS OF THE COMPANY AS PER MEMORANDUM OF ASSOCIATION ARE:- 1. To carry on all or any of the business of manufacturers, importers, exporters, buyers, sellers, and distributing agents of and dealers in all kinds of patent pharmaceuticals, medicinal and medicated preparations, patent medicines, drugs, herbs, and in pharmaceutical, medicinal, proprietary and industrial preparations, compounds and articles of all kinds, and chemical manufacturers. SUBSIDIARY COMPANY The company has no subsidiary. 2003 - company's modern formulation plant at Sihor, Gujarat,has received WHO-GMP ertificationas ,as laid down by world health organization, Geneva. 2004 -Jenburkt Pharmaceuticals Ltd has been Declares Dividend at Rs 0.70 per equity share each of Rs 10 has been declared. 2005 -Jenburkt Pharmaceuticals Ltd has recommended a dividend @ 10% on Equity Shares of the Company. 2006 -Jenburkt Pharmaceuticals Ltd has recommended a dividend @ 12.5% on Rs 10/- paid up Equity Shares of the Company. 2007 -Jenburkt Pharmaceuticals Ltd has recommended a dividend of 12.5% per equity share of Rs 10/- each. -The Company is in receipt of a prestigious credit rating Certification from NSIC-CRISIL. The Company has been awarded with the highest possible rating as "CRISIL SE 1A", under the captioned category. The rating indicates "Highest performance capability and High financial strength". -E-mail ID for Investor Complaints: investor@jenburkt.com 2008 -The Company has recommended a dividend of 12.5% equity share of Rs 10/-. 2009 -Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs 1.80 (18%) per equity share of Rs 10/- each. 2010 -Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs. 3.00 (30%) per equity shares of Rs. 10/- each. -The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi. 2011 -The Company has recommended a Dividend of Rs. 3.50 (35%) per equity share of Rs. 10/- each. -The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST" awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI). -The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates "Highest performance capability and High financial strength". 2012 -Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs. 3.50 (35%) per equity share of Rs. 10/- each. 2013 - Shri. Ashish U. Bhuta has been appointed as the Chairman and Managing Director of the Company 2014 -The Company has recommended a Dividend of Rs. 5.10 (51%) per equity share of Rs. 10/- each. -Ms. Devangi Sanjeev Shah has been appointed of Woman Director 2020 - Jenburkt, launched Favipiravir (Favivent) to fight COVID-19 2022 -The Company Launched a new product ZIXA STRONG on e-comerce websites.